Effects of electroconvulsive therapy on cognition and quality of life in schizophrenia

Tan, Xiao; Lim, Kenny Wai Kwong; Martin, Donel; Tor, Phern‐Chern

doi:10.47102/annals-acadmedsg.202292

Cited by 4 publications

(3 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In this issue of the Annals, Tan et al presented a critical and convincing report on the research of ECT and quality of life (QoL) among patients with schizophrenia. 6 The authors retrospectively examined the relationship between the use of acute ECT among 132 patients diagnosed with schizophrenia or schizophrenia spectrum disorder. They also examined the impact of acute ECT on psychiatric symptoms and cognition, with the ultimate aim of determining the association between ECTinduced psychiatric symptomatic change with changes and improvement in QoL.…”

mentioning

confidence: 99%

“…Tan et al have provided understanding of and shed light on the knowledge gap linking QoL and ECT among patients with schizophrenia. There is a dearth of research on this topic highlighted by Tan et al, 6 with previously only 3 publications reporting heterogeneous results in their investigation of QoL outcomes in patients with schizophrenia who underwent ECT. Multiple factors such as social, cultural, educational and economical background can interfere with the evaluation and interpretation of QoL, thus hindering the extrapolation of a conclusion even more so, as the construct of QoL is complex.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Bridging electroconvulsive therapy in schizophrenia with cognition and quality of life

Chhoa

Chee

2022

Ann Acad Med Singap

View full text Add to dashboard Cite

mentioning

confidence: 99%

mentioning

confidence: 99%

Bridging electroconvulsive therapy in schizophrenia with cognition and quality of life

Chhoa

Chee

2022

Ann Acad Med Singap

View full text Add to dashboard Cite

“…The benefit of ECT on the improvement of QoL in patients with depression has been documented in four well-controlled studies (Giacobbe et al, 2018). In contrast, in patients with schizophrenia, there is only one restrospective cohort study which found an improvement of QoL as measured by the Euroquol scale (EQ-5D) (Tan et al, 2022).…”

Section: Introductionmentioning

confidence: 99%

Caracterização do comprometimento cognitivo da esquizofrenia resistente a clozapina

Silva

View full text Add to dashboard Cite

of Life Scale (QoL), Family Burden (FBIS) and the Brain Derived Neurotrophic Factor (BDNF). Patients were defined as CRS according to the Treatment Response and Resistance in Psychosis (TRRIP) criteria, which includes assessment of clozapine plasma levels (≥ 350ng/mL) at baseline. MCCB assessment was done at baseline and after 20 sessions of ECT or Sham-ECT.The study was submitted for publication through two articles whose summary is found in the body of this dissertation and in its entirety in the annexes.Results: patients treated with ECT or Sham-ECT showed no significant differences at baseline except in terms of years of education, which was included as a covariate in all analyses. After the intervention period of 20 ECT/Sham-ECT treatment sessions, both groups did not show statistically significant differences, both in terms of the primary outcome and secondary outcomes including cognitive functioning assessed by the MCCB.

show abstract

Why You Should Collect Routine Clinical Data for ECT

Tor,

Barreiros,

Cao

et al. 2024

J ECT

View full text Add to dashboard Cite

C ontemporary medicine is faced with a multitude of challenges, 2 of which are determining which treatments are most effective in routine clinical care, and continually optimizing care in a finite resource environment. 1 These challenges were exemplified by the STAR*D studies, which not only revealed disappointing real-world remission rates for commonly used antidepressants, but also showed no difference in outcomes among any medication switches or augmentation strategies. 2 These trial results are mirrored in real-world practice, where antidepressant drug treatment is often quickly discontinued and patients switching drug therapy have the highest healthcare costs, implying poor outcomes. 3 Similarly for electroconvulsive therapy (ECT), the variation in worldwide practice is large and the corresponding outcomes were unclear. 4 The need for improvement is underscored by findings from the Community Study of ECT conducted across 7 hospitals in New York City, which showed substantial variability in long-term cognitive outcomes between hospitals, largely attributed to variation in ECT technique. 5 Enhanced knowledge about real-world clinical outcomes with ECT and the factors that affect these are therefore imperative for ensuring optimal care for our patients. WHAT IS THE CARE NETWORK?Measurement-based care (MBC), as exemplified by the Texas Medication Algorithm Project and the German Algorithm Project, has demonstrated benefits over usual care in terms of patient outcomes, quality of life, therapeutic relationship, shared decision-making, and research. Crucially, MBC has been successfully integrated as part of standard care in real-world settings. 6 For ECT, a model example of this is the Clinical Alliance and Research in ECT and Related Treatments (CARE) Network, published in this journal 7 and lauded by other systematic data collection networks. 8 The CARE Network aims to address the substantial heterogeneity in ECT treatment methods across clinical settings by facilitating MBC and understanding how variations in clinical practice relate to treatment outcomes. It introduces structured measurements to facilitate MBC, clinical auditing and benchmarking, and quantitative research based on real-world data.The CARE system involves a standardized set of core demographic, clinical, and ECT treatment outcomes, along with additional optional assessments for more detailed information.Assessments are conducted before ECT, during and after the acute ECT course, at the end of continuation ECT, and every 6 months during maintenance ECT treatment. Detailed demographic and clinical information, including treatment resistance, concurrent medication use, main indication for ECT, and comorbid diagnoses, are collected. Critical treatment factors such as dosing method, ECT frequency, seizure threshold, ECT treatment dose, number of ECT sessions in the acute course, and anesthetic procedure are also included.The main outcome indicator is the Clinical Global Impression scale 9 as the core transdiagnostic clinical outcome measure for effi...

show abstract

Effects of electroconvulsive therapy on cognition and quality of life in schizophrenia

Cited by 4 publications

References 39 publications

Bridging electroconvulsive therapy in schizophrenia with cognition and quality of life

Bridging electroconvulsive therapy in schizophrenia with cognition and quality of life

Caracterização do comprometimento cognitivo da esquizofrenia resistente a clozapina

Why You Should Collect Routine Clinical Data for ECT

Contact Info

Product

Resources

About